Microcap Ledger Cardiff Oncology, Inc. $CRDF
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- Shares outstanding
- 77,795,249 [10-Q 2026-08-11]
What the company doesAI summary of filing
Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor, in combination with standard-of-care cancer therapies. The company is evaluating onvansertib primarily in a Phase 2 randomized trial (CRDF-004) for first-line treatment of RAS-mutated metastatic colorectal cancer, with additional investigator-initiated trials ongoing in metastatic pancreatic cancer, small cell lung cancer, triple negative breast cancer, and chronic myelomonocytic leukemia. Cardiff has no product revenue and relies on clinical trial data and regulatory approvals to advance its single drug candidate toward potential commercialization. [10-K 2026-02-24]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $145.0K | −$21.58M | −$24.05M | $9.20M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | $593.0K | −$45.9K | −$37.92M | $17.47M | [10-K 2026-02-24] |
| FY ended Dec 2024 | $683.0K | −$45.4K | −$37.69M | $51.47M | [10-K 2026-02-24] |
- Quarterly cash burn
- −$12.03M
- Cash runway Estimate
- ~2.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 51,133,747 | [10-Q 2024-11-07] |
| 2025-02-20 | 66,524,294 | [10-K 2025-02-27] |
| 2025-05-01 | 66,525,854 | [10-Q 2025-05-08] |
| 2025-07-24 | 66,525,854 | [10-Q 2025-07-29] |
| 2025-10-30 | 67,360,564 | [10-Q 2025-11-06] |
| 2026-02-19 | 68,364,979 | [10-K 2026-02-24] |
| 2026-04-30 | 68,369,896 | [10-Q 2026-05-14] |
| 2026-08-06 | 77,795,249 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2025-02-27; declared effective 2025-05-13 [S-3 2025-02-27]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-14 | Pace Gary W | buy | 687,285 | $1.46 | [4 2026-07-16] |
| 2026-07-14 | Mohindru Mani | buy | 34,364 | $1.46 | [4 2026-07-16] |
| 2026-06-18 | Mohindru Mani | buy | 24,703 | $1.21 | [4 2026-06-22] |
| 2026-06-18 | Pace Gary W | buy | 30,000 | $1.22 | [4 2026-06-22] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-14 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-08-26 | DEF 14A | Proxy statement |
| 2026-08-14 | PRE 14A | Proxy statement |
| 2026-08-11 | 8-K | Results of operations |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-07-27 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-16 | 8-K | Material agreement entered; Other events |
| 2026-07-16 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-11 | 8-K | Shareholder vote results |
| 2026-06-03 | 8-K | Regulation FD disclosure |
| 2026-05-29 | 8-K | Material agreement entered |
| 2026-05-19 | 8-K | Other events |
Alerts for $CRDF
Email me when Cardiff Oncology, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.